Hornykiewicz O, Shannak K
Institute of Biochemical Pharmacology, University of Vienna, Austria.
J Neural Transm Suppl. 1994;42:219-27. doi: 10.1007/978-3-7091-6641-3_17.
Like idiopathic Parkinson's disease (iPD), Progressive Supranuclear Palsy (PSP) is characterized, inter alia, by a pronounced non-overlapping loss of dopamine (DA) in caudate, putamen and substantia nigra. Unlike iPD, in PSP the striatal DA loss is more severe in the caudate than in the putamen; this may contribute to the higher frequency of cognitive deficits in PSP. In contrast to iPD, in patients with PSP the serotonin (5-HT) levels in the basal ganglia are not significantly reduced, thus resulting in a relative predominance of the inhibitory serotonergic influences on the motor behaviour in these patients. It is suggested that combination of levodopa with a 5-HT receptor blocker may substantially improve the (poor) responsiveness of patients with PSP to DA substitution therapy.
与特发性帕金森病（iPD）一样，进行性核上性麻痹（PSP）的特征包括尾状核、壳核和黑质中多巴胺（DA）明显且不重叠的缺失。与iPD不同，在PSP中，尾状核的纹状体DA缺失比壳核更严重；这可能导致PSP中认知缺陷的发生率更高。与iPD相反，PSP患者基底神经节中的血清素（5-HT）水平没有显著降低，从而导致这些患者运动行为中抑制性血清素能影响相对占主导地位。有人提出，左旋多巴与5-HT受体阻滞剂联合使用可能会显著改善PSP患者对DA替代疗法的（较差）反应性。
